Skip to content
Study details
Enrolling now

Cladribine, Idarubicin, Cytarabine, and Quizartinib Trial

M.D. Anderson Cancer Center
NCT IDNCT04047641ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1/2

Target enrollment

80

Study length

about 8.2 years

Ages

18+

Locations

1 site in TX

What this study is about

This trial is testing the safety and effectiveness of cladribine, idarubicin, cytarabine, and quizartinib in treating acute myeloid leukemia or high-risk myelodysplastic syndrome. The treatment may involve medication to stop cancer cell growth.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Cladribine
  • 2.Take Cytarabine
  • 3.Take Idarubicin
  • +1 more

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Injection / IVInjection / IV

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

cladribine, cytarabine, idarubicin, quizartinib

Drug routes

injection, intravenous, injection (Injection), oral (Oral Tablet)

Endpoints

Primary: Event free survival (EFS), Incidence of adverse events

Secondary: Disease free survival (DFS), Overall survival (OS)

Body systems

Oncology, Musculoskeletal